Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) decided to create a new division for developing RCC-33, an anti-tumor drug, to cure colorectal cancer. It is on the backdrop of scaling up its efforts for clinical validation of its leading drug candidates. As part of this effort, the company establishes tie-ups with medical centers, engages in in-vivo clinical experiments, and prepares a dosage plan to request a pre-innovative new drug (IND) application meeting with the FDA.
CEO of Cannabics, Eyal Barad, said the company is developing a treatment colorectal cancer using a proprietary and innovative formulation – RCC-33. Until now, the company carried out several POC experiments at its in-house drug development facility. It decided to establish a dedicated facility for its leading drug candidates’ centralized and coordinated developmental efforts.
Erez Scapa as a Medical Director
Dr. Erez Scapa will assume the role of Medical Director for the new development facility. He will play a vital role in advising the plans for clinical validation of leading drugs in the future. Commenting on his role, Erez thanked the company for the trust reposed in him for this role. He is looking forward to assisting the company in developing a comprehensive clinical validation plan for RCC-33 to cure colorectal cancer.
According to Erez, more than 65% of patients with colorectal cancer in the US survive for five or more years. The developmental efforts at Cannabics are at the infant stage and ready to take the challenges ahead in developing a safe and effective cure for colorectal cancer and improving patients’ survival rates.
Ben-Ami Shor in Scientific Advisory Board
Dr. Ben-Ami Shor joined the scientific advisory board of Cannabics. She is an expert in enterology and invasive endoscopy and working at Tel-Aviv Israel based Sourasky Medical Center. Other members of the scientific advisory board include Erez and Prof. Zamir Halpern. She will play a critical role in designing and implementing the clinical validation plan of Cannabics for the leading drug – RCC-33 to provide an effective cure for colorectal cancer.
The research of Ben-Ami focuses on autoimmune diseases, innovative treatments, and mechanisms of action, obesity, billary disease, pancreatic diseases, and epidemiology.
 Will Establish A Dedicated Development Center For RCC-33 To Treat Colorectal Cancer){kind=link}